REVIEW PAPER
Application of bone turnover markers in skeletal and extra-skeletal conditions in children and adults
1
Department of Pediatric Nephrology, Medical University of Lublin, Lublin, Poland
Submission date: 2024-04-10
Final revision date: 2024-05-31
Acceptance date: 2024-06-12
Publication date: 2024-12-30
Corresponding author
Agnieszka Postępska
Department of Pediatric Nephrology, Medical University of Lublin, 6 prof. Antoniego Gębali St., 20-093 Lublin, Poland
Department of Pediatric Nephrology, Medical University of Lublin, 6 prof. Antoniego Gębali St., 20-093 Lublin, Poland
Pediatr Pol 2024;99(4):319-328
KEYWORDS
TOPICS
ABSTRACT
The assessment of bone health is challenging. It comprises bone histomorphometry, imaging techniques and laboratory parameters including bone turnover markers (BTMs). The latter are bone-derived products which can be measured in biological fluids, including blood and urine. Considering the disadvantages and limitations of imaging techniques, BTMs serve as an additional, non-invasive source of information about the metabolic activity of the entire skeleton. BTMs have found applications as research and clinical tools in a wide range of skeletal and extra-skeletal conditions, including diagnosis and treatment of osteoporosis. Unfortunately, their utility in routine clinical practice, especially in children, is still limited due to heterogenous methodology, intra- and inter patient variability, and a paucity of accurate reference ranges and approved guidelines. Therefore, there is a need for standardized clinical trials on currently available and new BTMs.
REFERENCES (121)
1.
Kenkre JS, Bassett JHD. The bone remodelling cycle. Ann Clin Biochem 2018; 55: 308-327.
2.
Schini M, Vilaca T, Gossiel F, et al. Bone turnover markers: basic biology to clinical applications. Endocr Rev 2023; 44: 417-473.
3.
Szulc P. Bone turnover: biology and assessment tools. Best Pract Res Clin Endocrinol Metab 2018; 32: 725-738.
4.
Messina C, Maffi G, Vitale JA, et al. Diagnostic imaging of osteoporosis and sarcopenia: a narrative review. Quant Imaging Med Surg 2018; 8: 86-99.
5.
Di Iorgi N, Maruca K, Patti G, et al. Update on bone density measurements and their interpretation in children and adolescents. Best Pract Res Clin Endocrinol Metab 2018; 32: 477-498.
6.
Blake GM, Siddique M, Frost ML, et al. Imaging of site specific bone turnover in osteoporosis using positron emission tomography. Curr Osteoporos Rep 2014; 12: 475-485.
7.
Eisenhauer A, Müllerb M, Heuser A, et al. Calcium isotope ratios in blood and urine: a new biomarker for the diagnosis of osteoporosis. Bone Reports 2019; 10: 100200. DOI: 10.1016/j.bonr.2019.100200.
8.
Ladang A, Rauch F, Delvin E, et al. Bone turnover markers in children: from laboratory challenges to clinical interpretation. Calcif Tissue Int 2023; 112: 218-232.
9.
Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 2017; 5: 908-923.
10.
Diemar SS, Møllehave LT, Quardon N, et al. Effects of age and sex on osteocalcin and bone-specific alkaline phosphatase – reference intervals and confounders for two bone formation markers. Arch Osteoporos 2020; 15: 26. DOI: 10.1007/s11657-020-00715-6.
11.
Diemar SS, Lylloff L, Rønne MS, et al. Reference intervals in Danish children and adolescents for bone turnover markers carboxy-terminal cross-linked telopeptide of type I collagen (β-CTX), pro-collagen type I N-terminal propeptide (PINP), osteocalcin (OC) and bone-specific alkaline phosphatase (bone ALP). Bone 2021; 146: 115879. DOI: 10.1016/j.bone.2021.115879.
12.
Tournis S, Yavropoulou MP, Polyzos SA, et al. Hypophosphatasia. J Clin Med 2021; 10: 5676. DOI: 10.3390/jcm10235676.
13.
Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget’s disease of bone in adults: a clinical guideline. J Bone Miner Res 2019; 34: 579-604.
14.
Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine 2012; 79: 20-25.
15.
Bauer DC, Black DM, Bouxsein ML, et al. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. J Bone Miner Res 2018; 33: 634-642.
16.
Diacinti D, Pisani D, Cipriani C, et al. Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate. Bone 2021; 143: 115608. DOI: 10.1016/j.bone.2020.115608.
17.
Rychłowska-Pruszyńska M, Gajewska J, Ambroszkiewicz J, et al. The levels of bone alkaline phosphatase BALP and soluble epidermal growth factor receptor 2 ECD/HER2 in pediatric patients with osteosarcoma during clinical treatment. Dev Period Med 2018; 22: 58-64.
18.
Leunga KS, Kumta SM, Fung KP. Clinical Study bone-specific alkaline phosphatase in plasma as tumour. Oncology 1996; 53: 275-280.
19.
Du WX, Duan SF, Chen JJ, et al. Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis. J Cancer Res Ther 2014; 10: C140-C143. DOI: 10.4103/0973-1482.145842.
20.
Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. Biochem Pharmacol 2017; 132: 1-8.
21.
Vanderschueren D, Gevers G, Raymaekers G, Devos P, Dequeker J. Calcified tissue international sex-and age-related changes in bone and serum osteocalcin. Calcif Tissue Int 1990; 46: 179-182.
22.
Darelid A, Nilsson M, Kindblom JM, Mellström D, Ohlsson C, Lorentzon M. Bone turnover markers predict bone mass development in young adult men: a five-year longitudinal study. J Clin Endocrinol Metab 2015; 100: 1460-1468.
23.
Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF. Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 1985; 4: 736-739.
24.
Geserick M, Vogel M, Eckelt F, et al. Children and adolescents with obesity have reduced serum bone turnover markers and 25-hydroxyvitamin D but increased parathyroid hormone concentrations – results derived from new pediatric reference ranges. Bone 2020; 132: 115124. DOI: 10.1016/j.bone.2019.115124.
25.
Vergnaud P, Garnero P, Meunier PJ, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol Metab 1997; 82: 719-724.
26.
Kalaiselvi VS, Prabhu K, Ramesh M, et al. The association of serum osteocalcin with the bone mineral density in post menopausal women. J Clin Diagn Res 2013; 7: 814-816.
27.
Bowden SA, Akusoba CI, Hayes JR, et al. Biochemical markers of bone turnover in children with clinical bone fragility. J Pediatr Endocrinol Metab 2016; 29: 715-722.
28.
Szymczuk V, Taylor J, Michel Z, et al. Skeletal disease acquisition in fibrous dysplasia: natural history and indicators of lesion progression in children. J Bone Miner Res 2022; 37: 1473-1478.
29.
Zeng H, Ge J, Xu W, et al. Type 2 diabetes is causally associated with reduced serum osteocalcin: a genomewide association and mendelian randomization study. J Bone Miner Res 2021; 36: 1694-1707.
30.
Madsen JOB, Jørgensen NR, Pociot F, et al. Bone turnover markers in children and adolescents with type 1 diabetes – a systematic review. Pediatr Diabetes 2019; 20: 510-522.
31.
Otani T, Mizokami A, Kawakubo-Yasukochi T, et al. The roles of osteocalcin in lipid metabolism in adipose tissue and liver. Adv Biol Regul 2020; 78: 100752. DOI: 10.1016/j.jbior.2020.100752.
32.
Luo Y, Ma X, Hao Y, et al. Association between serum osteocalcin level and visceral obesity in Chinese postmenopausal women. Clin Endocrinol (Oxf) 2015; 83: 429-434.
33.
Kim GS, Jekal Y, Kim HS, et al. Reduced serum total osteocalcin is associated with central obesity in Korean children. Obes Res Clin Pract 2014; 8: e201-e298. DOI: 10.1016/j.orcp.2012.12.003.
34.
Amin S, El Amrousy D, Elrifaey S, et al. Serum osteocalcin levels in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2018; 66: 117-121.
35.
Obri A, Khrimian L, Karsenty G, et al. Osteocalcin in the brain: from embryonic development to age-related decline in cognition. Nat Rev Endocrinol 2018; 14: 174-182.
36.
Bayer M. Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0-18 years. Osteoporos Int 2014; 25: 729-736.
37.
Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009; 24: 389-397.
38.
Saad MA, Aboelwafa RA, Elsayed EH. Could procollagen type I N-terminal propeptide (PINP) and bone alkaline phosphatase (B-ALP) be valid alternative diagnostic markers to dual X-ray absorptiometry (DEXA) in elderly females with osteoporosis? An Egyptian radiological and laboratory monocentric study. Egypt Rheumatol Rehabil 2021; 48: 20: https://doi.org/10.1186/s43166....
39.
Johansson H, Odén A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 2014; 94: 560-567.
40.
Tian A, Ma J, Feng K, et al. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res 2019; 14: 68. DOI: 10.1186/s13018-019-1100-6.
41.
Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 2016; 27: 21-31.
42.
Gillett MJ, Vasikaran SD, Inderjeeth CA. The role of PINP in diagnosis and management of metabolic bone disease. Clin Biochem Rev 2021; 42: 3-10.
43.
Krege JH, Lane NE, Harris J, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 2014; 25: 2159-2171.
44.
Tsujimoto M, Chen P, Miyauchi A, et al. PINP as an aid for monitoring patients treated with teriparatide. Bone 2011; 48: 798-803.
45.
Alonso S, Ferrero E, Donat M, et al. The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy. J Endocrinol Invest 2012; 35: 640-644.
46.
Al Nofal AA, Altayar O, BenKhadra K, et al. Bone turnover markers in Paget’s disease of the bone: a systematic review and meta-analysis. Osteoporos Int 2015; 26: 1875-1891.
47.
El Amrousy D, El-Afify D, Shabana A. Relationship between bone turnover markers and oxidative stress in children with type 1 diabetes mellitus. Pediatr Res 2021; 89: 878-881.
48.
Maggio ABR, Ferrari S, Kraenzlin M, et al. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. J Pediatr Endocrinol Metab 2010; 23: 697-707.
49.
Li H, Wen Y, Liu P, et al. Characteristics of bone metabolism in postmenopausal women with newly diagnosed type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2021; 95: 430-438.
50.
Vilaca T, Schini M, Harnan S, et al. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update. Bone 2020; 137: 115457. DOI: 10.1016/j.bone.2020.115457.
51.
Koopmans N, de Jong IJ, Breeuwsma AJ, et al. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007; 178: 849-853.
52.
Jaeger B, Tauer J, Ulmer A, et al. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit 2012; 18: 721-728.
53.
Vihinen MK, Kolho KL, Ashorn M, et al. Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 2008; 159: 693-698.
54.
Tridimas A, Milan A, Marks E. Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): the choice of assay makes a difference. Ann Clin Biochem 2021; 58: 528-536.
55.
Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem 2017; 63: 464-474.
56.
De Melo VCP, Ferreira PRS, Ricardi LO, et al. Definition of reference ranges for β-isomerized carboxy-terminal telopeptide collagen type i for children and adolescents. JPEM 2018; 31: 637-640.
57.
Li M, Li Y, Deng W, et al. Chinese bone turnover marker study: reference ranges for C-terminal telopeptide of type i collagen and procollagen I N-terminal peptide by age and gender. PLoS One 2014; 9: e103841. DOI: 10.1371/journal.pone.0103841.
58.
Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96: 972-980.
59.
De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from a phase iii trial. Arthritis Rheumatol 2015; 67: 840-848.
60.
Karsdal MA, Woodworth T, Henriksen K, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis – current and future applications, limitations and opportunities. Arthritis Res Ther 2011; 13: 215.
61.
Alexandersen P, Peris P, Guañabens N, et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget’s disease of bone. J Bone Miner Res 2005; 20: 588-595.
62.
Chai X, Yinwang E, Wang Z, et al. Predictive and prognostic biomarkers for lung cancer bone metastasis and their therapeutic value. Front Oncol 2021; 11: 692788. DOI: 10.3389/fonc.2021.692788.
63.
Chen S, Wang L, Qian K, et al. Establishing a prediction model for prostate cancer bone metastasis. Int J Biol Sci 2019; 15: 208-220.
64.
Muggeo P, Grassi M, D’Ascanio V, et al. Bone remodeling markers in children with acute lymphoblastic leukemia after intensive chemotherapy: the screenshot of a biochemical signature. Cancers (Basel) 2023; 15: 2554. DOI: 10.3390/cancers15092554.
65.
Vervloet MG, Brandenburg VM, Bover J, et al. Circulating markers of bone turnover. J Nephrol 2017; 30: 663-670.
66.
Nenonen A, Cheng S, Ivaska KK, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res; 20: 1804-1812.
67.
Zhang J, Zeng H, Fu S, et al. Changes in the Dickkopf-1 and tartrate-resistant acid phosphatase 5b serum levels in preschool children with nephrotic syndrome. Biomed Rep 2016; 4: 605-608.
68.
Mokhtar GM, Tantawy AAG, Hamed AAS, et al. Tartrate-resistant acid phosphatase 5b in young patients with sickle cell disease and trait siblings: relation to vasculopathy and bone mineral density. Clin Appl Thromb Hem 2017; 23: 64-71.
69.
Bellini G, Pinto D Di, Tortora C, et al. The role of mifamurtide in chemotherapy-induced osteoporosis of children with osteosarcoma. Curr Cancer Drug Targets 2017; 17: 650-656.
70.
Hoshi M, Oebisu N, Iwai T, et al. High tartrate-resistant acid phosphatase (TRACP 5b) level in cystic fluid is a significant prognostic marker for postoperative recurrence in solitary bone cysts. J Child Orthop 2022; 16: 519-527.
71.
Karakaş NM, Kınık ST, Özdemir B, et al. Congenital hypothyroidism and bone remodeling cycle. JCRPE J Clin Res Pediatr Endocrinol 2017; 9: 106-110.
72.
Sharifi M, Ereifej L, Lewiecki EM. Sclerostin and skeletal health. Rev Endocr Metab Disord 2015; 16: 149-156.
73.
Maeda K, Kobayashi Y, Koide M, et al. The regulation of bone metabolism and disordersby wnt signaling. Int J Mol Sci 2019; 20: 1694. DOI: 10.3390/ijms20071694.
74.
Kirmani S, Amin S, McCready LK, et al. Sclerostin levels during growth in children. Osteoporos Int 2012; 23: 1123-1130.
75.
Arasu A, Cawthon PM, Lui LY, et al. Serum sclerostin and risk of hip fracture in older caucasian women. J Clin Endocrinol Metab 2012; 97: 2027-2032.
76.
Sebastian A, Loots GG. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models. Metabolism 2018; 80: 38-47.
77.
Shalash MAM, Rohoma KH, Kandil NS, et al. Serum sclerostin level and its relation to subclinical atherosclerosis in subjects with type 2 diabetes. J Diabetes Complications 2019; 33: 592-597.
78.
Wędrychowicz A, Sztefko K, Starzyk JB. Sclerostin and its significance for children and adolescents with type 1 diabetes mellitus (T1D). Bone 2019; 120: 387-392.
79.
Wędrychowicz A, Sztefko K, Starzyk JB. Sclerostin and its association with insulin resistance in children and adolescents. Bone 2019; 120: 232-238.
80.
Bouquegneau A, Evenepoel P, Paquot F, et al. Sclerostin within the chronic kidney disease spectrum. Clinica Chimica Acta 2020; 502: 84-90.
81.
Guven S, Gokce I, Cicek N, et al. Sclerostin and osteoprotegerin: New markers of chronic kidney disease mediated mineral and bone disease in children. J Pediatr Endocrinol Metab 2020; 33: 1383-1390.
82.
Singh S, Dutta S, Khasbage S, et al. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis. Osteoporos Int 2022; 33: 1-12.
83.
Ward LM, Rauch F. Anabolic therapy for the treatment of osteoporosis in childhood. Curr Osteoporos Rep 2018; 16: 269-276.
84.
Saito T, Fukumoto S. Fibroblast growth factor 23 (FGF23) and disorders of phosphate metabolism. Int J Pediatr Endocrinol 2009; 2009: 496514. DOI: 10.1155/2009/496514.
85.
Kung CJ, Haykir B, Schnitzbauer U, et al. Fibroblast growth factor 23 leads to endolysosomal routing of the renal phosphate cotransporters NaPi-IIa and NaPi-IIc in vivo. Am J Physiol Renal Physiol 2021; 321: 785-798.
86.
Ho BB, Bergwitz C. FGF23 signalling and physiology. J Mol Endocrinol 2021; 66: 23-32.
87.
Brescia V, Fontana A, Lovero R, et al. Determination of iFGF23 upper reference limits (URL) in healthy pediatric population, for its better correct use. Front Endocrinol (Lausanne) 2022; 13: 1018523. DOI: 10.3389/fendo.2022.1018523.
88.
Athonvarangkul D, Insogna KL. New therapies for hypophosphatemia-related to FGF23 excess. Calcif Tissue Int 2021; 108: 143-157.
89.
Florenzano P, Hartley IR, Jimenez M, et al. Tumor-induced osteomalacia. Calcif Tissue Int 2021; 108: 128-142.
90.
Linglart A, Imel EA, Whyte MP, et al. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 2022; 107: 813-824.
91.
Sirikul W, Siri-Angkul N, Chattipakorn N, et al. Fibroblast growth factor 23 and osteoporosis: evidence from bench to bedside. Int J Mol Sci 2022; 23: 2500. DOI: 10.3390/ijms23052500.
92.
Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
93.
Damasiewicz MJ, Toussaint ND, Polkinghorne KR. Fibroblast growth factor 23 in chronic kidney disease: new insights and clinical implications. Nephrology 2011; 16: 261-268.
94.
Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
95.
Mitsnefes MM, Betoko A, Schneider MF, et al. FGF23 and left ventricular hypertrophy in children with CKD. Clin J Am Soc Nephrol 2018; 13: 45-52.
96.
Bai Z, Fang F, Xu Z, et al. Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children. BMC Pediatr 2018; 18: 192. DOI: 10.1186/s12887-018-1175-y.
97.
Ali FN, Hassinger A, Price H, Langman CB. Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study. Pediatr Nephrol 2013; 28: 959-962.
98.
Prud’homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho antiaging protein and therapeutic considerations. Front Aging 2022; 3: 931331. DOI: 10.3389/fragi.2022.931331.
99.
Donate-Correa J, Martín-Carro B, Cannata-Andía JB, et al. Klotho, oxidative stress, and mitochondrial damage in kidney disease. Antioxidants (Basel) 2023; 12: 239. DOI: 10.3390/antiox12020239.
100.
Xu Y, Sun Z. Molecular basis of klotho: from gene to function in aging. Endocr Rev 2015; 36: 174-193.
101.
Gkentzi D, Efthymiadou A, Kritikou D, et al. Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone 2014; 66: 8-14.
102.
Kresovich JK, Bulka CM. Low serum Klotho associated with all-cause mortality among a nationally representative sample of American adults. J Gerontol A Biol Sci Med Sc 2022; 77: 452-456.
103.
Kuro-o M. Klotho and aging. Biochim Biophys Acta Gen Subj 2009; 1790: 1049-1058.
104.
Kanbay M, Demiray A, Afsar B, et al. Role of Klotho in the development of essential hypertension. Hypertension 2021; 77: 740-750.
105.
Quarles LD. Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions. Curr Opin Nephrol Hypertens 2019; 28: 16-25.
106.
Yu T, Dou C, Lu Y, et al. Klotho upregulates the interaction between RANK and TRAF6 to facilitate RANKL-induced osteoclastogenesis via the NF-κB signaling pathway. Ann Transl Med 2021; 9: 1499. DOI: 10.21037/atm-21-4332.
107.
Jiang J, Liu Q, Mao Y, et al. Klotho reduces the risk of osteoporosis in postmenopausal women: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES). BMC Endocr Disord 2023; 23: 151. DOI: 10.1186/s12902-023-01380-9.
108.
Baud’huin M, Duplomb L, Teletchea S, et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev 2013; 24: 401-409.
109.
Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9 (Suppl 1): S1. DOI: 10.1186/ar2165.
110.
Zhang Y, Liang J, Liu P, et al. The RANK/RANKL/OPG system and tumor bone metastasis: potential mechanisms and therapeutic strategies. Front Endocrinol (Lausanne) 2022; 13: 1063815. DOI: 10.3389/fendo.2022.1063815.
111.
Polyzos SA, Cundy T, Mantzoros CS. Juvenile Paget disease. Metabolism 2018; 80: 15-26.
112.
Ding J, Zhang C, Guo Y. The association of OPG polymorphisms with risk of osteoporotic fractures: a systematic review and meta-analysis. Medicine (Baltimore) 2021; 100: E26716. DOI: 10.1097/MD.0000000000026716.
113.
Paternoster L, Ohlsson C, Sayers A, et al. OPG and RANK polymorphisms are both associated with cortical bone mineral density: findings from a metaanalysis of the Avon longitudinal study of parents and children and Gothenburg osteoporosis and obesity determinants cohorts. J Clin Endocrinol Metab 2010; 95: 3940-3948.
114.
Veshnavei HA. Evaluation of the serum level of osteoprotegerin and bone mineral density in postmenopausal women. Int J Physiol Pathophysiol Pharmacol 2022; 14: 10-15.
115.
Azizieh FY, Shehab D, Jarallah K, et al. Circulatory levels of RANKL, OPG, and oxidative stress markers in postmenopausal women with normal or low bone mineral density. Biomark Insights 2019; 14: 1177271919843825. DOI: 10.1177/1177271919843825.
116.
Dobnig H, Hofbauer LC, Viereck V, et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporosis Int 2006; 17: 693-703.
117.
Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013; 167: 1924-1928.
118.
Chrysis D, Efthymiadou A, Mermigka A, et al. Osteoprotegerin, RANKL, ADMA, and fetuin – a serum levels in children with type I diabetes mellitus. Pediatr Diabetes 2017; 18: 277-282.
119.
Chapurlat RD, Confavreux CB. Novel biological markers of bone: from bone metabolism to bone physiologya. Rheumatology (Oxford) 2016; 55: 1714-1725.
120.
Gennari L, Bianciardi S, Merlotti D. MicroRNAs in bone diseases. Osteoporos Int 2017; 28: 1191-1213.
121.
Faienza MF, Ventura A, Delvecchio M, et al. High sclerostin and dickkopf-1 (DKK-1) serum levels in children and adolescents with type 1 diabetes mellitus. J Clin Endocrinol Metab 2017; 102: 1174-1181.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
